AN ASSOCIATION between levels of circulating immune complexes (CIC) and disease activity has been reported in several types of cancer (Robins & Baldwin, 1978) . The antigen components of CIC have been characterized in some virusinduced animal tumours and shown to be tumour products (Tucker et al., 1978; Theofilopoulos et al., 1978) . In human cancer, components of CIC have only been identified in a few instances, where a particular antigen such as CEA (Harvey et al., 1978) or ACTH (Havemann et al., 1979) had been specifically sought.
Several assays for CIC depend on the ability of polyethylene glycol (PEG) to precipitate immune complexes from serum under conditions in which either free antibody or free antigen are soluble (Creighton et al., 1973; Zubler et al., 1977; Digeon et al., 1977; Poulton et al., 1978) . It was proposed that individual components of CIC might be identified by analysis of PEG precipitates. This paper describes Na Dod SO4 polyacrylamide slab gel electrophoresis (PAGE) analysis of PEG precipitates of serum from patients with Hodgkin's disease and non-Hodgkin's lymphoma, and identification of a protein the presence of which correlates with disease activity.
The patients studied were attending the Department of Medical Oncology at Charing Cross Hospital for treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Control sera were obtained Accepted 14 November 1979 from healthy laboratory and nursing staff, patients with other malignancies, and hospital inpatients and outpatients with non-malignant conditions. Serum was stored (before processing) for up to 14 days at 4°C' after addition of 0'5% sodium azide.
3.500 PEG precipitation was performed by a modification of the method of Digeon et al. (1977) . 160 pl of serum was added to 540 1l 0d1M borate buffer (pH 8.4) and mixed with 700 1l of 70, PEG 6000 (BDH) in borate buffer. After standing overnight at 4°C and washing in 3-5% PEG, the precipitate was taken up in 0-IN NaOH for measurement of absorbance at 280 nm. The protein was then reprecipitated in 10% trichloracetic acid and examined by PAGE (Studier, 1973) in non-reducing conditions using the discontinuous buffer system (Laemmli, 1970) . Apparent mol. wts were determined by electrophoresis under reducing conditions. The gels were stained for protein with Coomassie blue.
The components of PEG precipitates were demonstrated by PAGE in which proteins are separated according to their mol. wt. Normal appearances are shown in Fig. 1 23,000 was identified. The presence of T23 correlated with disease activity. This is illustrated in Fig. 1 , in which T23 was present before treatment and disappeared with successful cytotoxic chemotherapy. Of 19 patients with Hodgkin's disease who were studied (Table I) T23 was detected in 7/9 with active disease, but in only 3/11 in complete remission. Of these 3, one relapsed within 1 month of the positive result, a second became positive 3 weeks after stopping chemotherapy and relapsed clinically 7 months later. The third patient remains clinically free from disease 1 year after the positive result.
Non-Hodgkin's lymphoma
A protein of the same apparent mol. wt as found in Hodgkin's disease was also present in serum of some patients with non-Hodgkin's lymphoma. This will be referred to similarly as T23. Fig. 2 illustrates how T23 disappeared from the serum of a patient with an immunoblastic lymphoma as tumour involving the marrow responded to cytotoxic chemotherapy, allowing the restoration of haemopoiesis. Table II The fact that T23 was found most readily in material precipitated from serum by 355% PEG is compatible with the presence of T23 in the form of an immune complex which is then split up by the conditions required for PAGE. However, several proteins are precipitated from normal serum in these conditions (Fig. 1, Track 4) indicating that T23 could also be isolated because it is complexed with a material other than an antibody or by virtue of its individual physicochemical characteristics.
Experiments to investigate these alternatives and for further clinical and immunological characterization of T23 are in progress. It seems likely that more specific and sensitive assays for T23 can be developed, permitting investigations of its site of production and of whether its early promise as a tumour marker can be confirmed and extended.
